|
|
||||||||
|
FJ
EXPRESS SUMMARY ARTICLE The Full-length version of this article is also available, published online September 24, 2004 as doi:10.1096/fj.04-2062fje. |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Laboratorio de Neuroquímica Retiniana y Oftalmología Experimental, Departamento de Bioquímica Humana, Facultad de Medicina, Universidad de Buenos Aires, CONICET, Buenos Aires, Argentina
1 Correspondence: Departamento de Bioquímica Humana, Facultad de Medicina, UBA. Paraguay 2155, 5°P, (1121), Buenos Aires, Argentina. E-mail: ruthr{at}fmed.uba.ar
SPECIFIC AIMS
The original aim of this study was to analyze the effect of melatonin on the glutamate/glutamine cycle activity in the hamster retina.
Glutamate is the main excitatory neurotransmitter in the retina but is neurotoxic when present in excessive amounts. The metabolic dependence of glutamatergic neurons on glia via the glutamate/glutamine cycle to provide the precursor for neurotransmitter glutamate is well established. An appropriate clearance of synaptic glutamate is required for normal function of retinal excitatory synapses and to prevent neurotoxicity. It was demonstrated that melatonin has a neuroprotective effect against glutamate-induced excitotoxicity in several systems. However, the full range of physiological actions and mechanisms involved in the effects of melatonin is not completely understood.
For the first time, we demonstrate in the present report that physiological concentrations of melatonin significantly modulate the retinal glutamate/glutamine cycle activity.
PRINCIPAL FINDINGS
CONCLUSIONS AND SIGNIFICANCE
Taken together, these results indicate that melatonin, probably through a redundant mechanism, may contribute to a decrease in synaptic glutamate concentrations. This effect could provide new insight into the neuroprotective potential of melatonin.
An increase in GS induced by glucocorticoids provides neuroprotection in different tissues, including the retina. Physiological levels of glucocorticoids regulate expression of this enzyme by stimulating transcription of the gene, taking
24 h. This might explain why glucocorticoids must be supplied early to achieve a beneficial effect and suggests that only in programmed neurological interventions might prophylactic administration of glucocorticoids be advisable. In contrast, since the observed effect of melatonin was much faster, treatment with methoxyindole may circumvent this obstacle. Moreover, this beneficial effect of melatonin may be further improved by its effect on glutamate uptake, glutaminase activity, and the nitridergic pathway. In summary, these findings suggest that treatment with melatonin could be considered as a new approach to handling glutamate-mediated neuronal degeneration.
|
FOOTNOTES
To read the full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.04-2062fje;
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |